Differential nigral expression of Bcl-2 protein family in chronically haloperidol and clozapine-treated rats: Role in neurotoxicity and stereotyped behavior

Experimental Neurology

Volumn 203, Issue 2, 2007, Pages 302-308

  Saldana M ^a   Bonastre, M ^a   Aguilar, E ^a   Marin, C ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE TRANSPORTER; HALOPERIDOL; NEUROLEPTIC AGENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; RAT; STEREOTYPY; SUBSTANTIA NIGRA; TARDIVE DYSKINESIA; WESTERN BLOTTING;

ANIMALS; ANTIPSYCHOTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CLOZAPINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HALOPERIDOL; MALE; NEOSTRIATUM; NEUROTOXICITY SYNDROMES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA;

EID: 33846453320     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.08.009     Document Type: Article

References (78)

1. Adams J.M., and Cory S. The bcl-2 family: arbiters of cell survival. Science 28 (1998) 1322-1326
2. Andreassen O.A., and Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rat. Implications for tardive dyskinesia?. Prog. Neurobiol. 61 (2000) 525-541
3. Andreassen O.A., Ferrante R.J., Aamo T.O., Beal M.F., and Jorgensen H.A. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122 (2003) 717-725
4. Bai O., Zhang H., and Li X.M. Antipsychotic drugs clozapine and olanzapine upregulated bcl2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res. 1010 (2004) 81-86
5. Bauer R., Mayr A., Lederer W., Needham P.L., Kilpatrick I.C., Fleischhacker W.W., and Marksteiner J. Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs. Neuropsychopharmacology 23 (2000) 46-55
6. Behl C., Rupprecht R., Skutella T., and Holsboer F. Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro. NeuroReport 7 (1995) 360-364
7. Bloomquist J., King E., Wright A., Mytilineou C., Kimura K., and Castagnoli N. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J. Pharmacol. Exp. Ther. 270 (1994) 822-830
8. Bubser M., and Deutch A.Y. Differential effects of typical and atypical antipsychotic drugs on striosome and matrix compartments of the striatum. Eur. J. Neurosci. 15 (2002) 713-720
9. Burger M.E., Fachineto R., Alves A., Callegari L., and Rocha J.B.T. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain uptake and elicit orofacial dyskinesia in rats. Brain Res. 1031 (2005) 202-210
10. Burt D.R., Creese I., and Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196 (1977) 326-328
11. Casey D.E. Tardive dyskinesia-Pathophysiology. Psychopharmacology: The Four Generation of Progress (1995), Raven Press, New York 1497-1502
12. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J. Clin. Psychiatry 61 (2000) 5-9
13. Dalgalarrondo P., and Gattaz W.F. Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration on neuroleptic treatment. Neur. Arch. Psychiatry Clin. Neurosci. 244 (1994) 272-277
14. Davies J.C. The bcl-2 family of proteins, and the regulation of cell survival. Trends Neurosci. 18 (1995) 355-358
15. Dean C.E. Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia?. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30 (2006) 174-189
16. Diederich N.J., and Goetz C.G. Drug-induced movement disorders. Neurol. Clin. 16 (1998) 125-139
17. Ernst A.M. Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia 10 (1967) 316-323
18. Eyles D.W., Avent K.M., Stedman T.J., and Pond S.M. Two pyridinium metabolites of haloperidol are present in the brain of patients at postmortem. Life Sci. 60 (1997) 529-534
19. Fibiger H.C., and Lloyd K.G. Neurobiological susbtrates of tardive dyskinesias: the GABA hypothesis. Trends Neurosci. 7 (1984) 462-464
20. Fray P.J., Sahakian B.J., Robbins T.W., Koob G.F., and Iversen S.D. An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology 69 (1980) 253-259
21. Gale K. Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283 (1980) 569-570
22. Galili-Mosberg R., Gil-Ad I., Weizman A., Melamed E., and Offen D. Haloperidol-induced neurotoxicity-Possible implications for tardive dyskinesia. J. Neural Transm. 107 (2000) 479-490
23. Glazer G.W., Camandola S., and Mattson M.P. NF-κB mediates the cell survival-promoting action of an activity-dependent neurotrophic factor peptide. J. Neurochem. 75 (2000) 101-108
24. Gunne L.M., Haggstrom J.E., and Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 30 (1996) 347-349
25. L in Parkinson's disease. Neurobiol. Dis. 10 (2002) 28-32
26. Horowitz J.M., Pastor D.M., Goyal A., Kar S., Ramdeen N., Hallas B.H., and Torres G. Bax-protein-immunoreactivity in midbrain neurons of Parkinsons' disease patients. Brain Res. Bull. 62 (2003) 55-61
27. Ikeda H., Adachi K., Hasegawa M., Sato M., Hirose N., Koshikawa N., and Cools A.R. Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia. J. Neural. Transm. 106 (1999) 1205-1216
28. Jarskog L.F., Selinger E.S., Lieberman J.A., and Gilmore J.H. Apoptotic proteins in the temporal cortex in schizophrenia: high bax/bcl-2 ratio without caspase-3 activation. Am. J. Psychiatry 161 (2004) 109-115
29. Jarskog, L.F., Gilmore, J.H., Glantz, L.A., Gable, K.L., German, T.T., Tong, R.I., Lieberman, J.A., in press. Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics, Neuropsychopharmacology.
30. Jellinger K.A. Cell death mechanisms in Parkinson's disease. J. Neural Transm. 107 (2000) 1-29
31. Kane J.M. Tardive dyskinesia: epidemiology and clinical presentation. Psychopharmacology: The Fourth Generation of Progress vol. 39 (1995), Raven Press, New York 1485-1495
32. Kitamura Y., Shimohama S., Kanoshima W., Ota T., Matsuoka Y., Nomura Y., Smith M.A., Perry G., Whitehouse P.J., and Taniguchi T. Alteration of protein regulating apoptosis, bcl-2, bclx, bax, bak, bad, ICH-1 and CPP32 in Alzheimer's disease. Brain Res. 780 (1998) 260-289
33. Klawans H., and Rubovits R. An experimental model of tardive dyskinesia. J. Neural Transm. 3 (1972) 235-246
34. Kramer B.C., and Mytilineou C. Alterations in the cellular distribution of bcl-2, bcl-x and bax in the adult rat substantia nigra following striatal 6-hydroxydopamine lesions. J. Neurocytol. 33 (2004) 213-223
35. Levinson A.J., Garside S., Rosebush P.I., and Mazurek M.F. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience 84 (1998) 201-211
36. Li S., Cui N., Zhang Z., Zhao X., Yu S., and Xie K. Effect of subchronic exposure to acrylamide induced on the expression of bcl-2, bax and caspase-3 in the rat nervous system. Toxicology 217 (2006) 46-53
37. Lindsten T., Zong W., and Thompson C.B. Defining the role of the Bcl-2 family of proteins in the nervous system. Neuroscientist 11 (2005) 10-15
38. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
39. Marchese G., Casu M.A., Bartholini F., Ruiu S., Saba P., Gessa G.L., and Pani L. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigrostriatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur. J. Neurosci. 15 (2002) 1187-1196
40. Marchese G., Bartholini F., Ruiu S., Casti P., Casu G.L., and Pani L. Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. Eur. J. Pharmacol. 483 (2004) 65-69
41. Marin C., and Chase T.N. D-1 but not D-2 dopamine stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor upregulation. Eur. J. Pharmacol. 231 (1993) 191-196
42. Marin C., Engber T.M., Bonastre M., Chase T.N., and Tolosa E. Effect of long-term haloperidol treatment on striatal neuropeptides: relation to stereotyped behavior. Brain Res. 731 (1996) 57-62
43. Marin C., Bonastre M., and Tolosa E. Striatal c-fos levels do not correlate with haloperidol-induced behavioral supersensitivity. Synapse 23 (1996) 89-93
44. Marshall K.A., Daniels S.E., Cairns N., Jenner P., and Halliwell B. Upregulation of the antiapoptotic protein bcl-2 may be an early event in the neurodegeneration: studies on Parkinson's and incidental Lewy body disease. Biochem. Biophys. Res. Commun. 240 (1997) 84-87
45. Mazurek M.F., Savedia S.M., Bobba R.S., Garside S., and Rosebush P.I. Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal. J. Neurol. Neurosurg. Psychiatry 64 (1998) 799-801
46. Merry D.E., and Korsmeywer S.J. Bcl-2 gene family in the nervous system. Annu. Rev. Neurosci. 20 (1997) 245-267
47. Meshul C.K., Janowsky A., Casey D.E., Stalbaumer R.K., and Taylor B. Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens and medial prefrontal cortex. Psychopharmacology 106 (1992) 45-52
48. Meshul C.K., Stallbaumer R.K., Taylor B., and Janowsky A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 648 (1994) 181-195
49. Minon C.C., Andreasen N.C., Arndt S., Swayze II V.W., and Cohen G.A. MRI abnormalities in tardive dyskinesia. Psychiatry Res. 40 (1991) 157-166
50. Mitchell I.J., Cooper A.C., Griffiths M.R., and Cooper A.J. Acute administration of haloperidol induces apoptosis of neurons in the striatum and substantia nigra in the rat. Neuroscience 109 (2002) 89-99
51. Mladenovic A., Perovic M., Raicevic N., Kanazir S., Rakic L., and Ruzdijic S. 6-Hydorxydopamine increases the level of TNF-α and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats. Brain Res. 996 (2004) 237-245
52. Mogi M., Harada M., Kondo T., Mizuno Y., Narabayashi H., Riederer P., and Nagatsu T. Bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci. Lett. 215 (1996) 137-139
53. Naidu P.S., and Kulkami S.K. Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats. Eur. J. Pharmacol. 430 (2001) 295-298
54. Noh J.S., Ko H.W., Ryu B.R., Sohn S., and Gwag B.J. Haloperidol-induced neuronal apoptosis: blockade by neurotrophins and IGFs. Abstr.-Soc. Neurosci. 24 (1997) 1046
55. Noh J.S., Kang H.J., Kim E.Y., Sohn S., Chung Y.K., Kim S.U., and Gwag B.J. Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH2-terminal protein kinase. J. Neurochem. 75 (2000) 2327-2334
56. 2A receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J. Neurochem. 65 (1995) 2057-2064
57. Peacock L., and Gerlach J.A. Reanalysis of the dopamine theory of tardive dyskinesia the hypothesis of dopamine D1/D2 imbalance. Neuroleptic-Induced Movement Disorders (1997), Cambridge Univ. Press, New York 141-160
58. Pérez-Navarro E., Gavaldà N., Gratacós E., and Alberch J. Brain-derived neurotrophic factor prevent changes in bcl-2 family members and caspase activation induced by excitotoxicity in the striatum. J. Neurochem. 92 (2005) 678-691
59. Perier C., Tieu K., Guégan C., Caspersen C., Jackson-Lewis V., Carelli V., Martinuzzi A., Hirano M., Przedborski S., and Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc. Natl. Acad. Sci. 102 (2005) 19126-19131
60. Reed J.C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124 (1994) 1-6
61. Rollema H., Skolnik M., D'Engelbronner J., Igarashi K., Usuki E., and Castagnoli Jr.N. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268 (1994) 380-387
62. Sagarab Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 71 (1998) 1002-1012
63. Saldaña M., Bonastre M., Aguilar E., and Marin C. Role of nigral NFkB p50 and p65 subunits expression in haloperidol-induced neurotoxicity and stereotyped behavior in rats. Eur. Neuropsychopharmacol. 16 (2006) 491-497
64. Satou T., Cummings B.J., and Cotman C.W. Immunoreactivity for bcl-2 protein within neurons in the Alzheimer's disease brain increases with disease severity. Brain Res. 697 (1995) 35-43
65. Shacka J.J., and Roth K.A. Regulation of neuronal cell death and neurodegeneration by members of the bcl-2 family: therapeutic implications. Current drug targets. CNS Neurol. Dis. 4 (2005) 25-39
66. Skoblenick K.J., Castellano J.M., Rogoza R.M., Dyck B.A., Thomas N., Gabriele J.P., Chong V.Z., and Mishra R.K. Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine, treatment. Apoptosis 11 (2006) 663-672
67. Tarsy D., and Baldessarini R. Behavioral hypersensitivity to apomorphine following chronic treatment with drugs which interfere with synaptic function of catecholamines. Neuropharmacology 13 (1974) 927-940
68. Tortosa A., López E., and Ferrer I. Bcl-2 and bax expression in Lewy bodies from patients with Parkinson's disease and diffuse Lewy body disease. Neurosci. Lett. 238 (1997) 78-80
69. Tsai G.C., Golf D.C., Chang R.W., Flood J., Baet L., and Coyle J.T. Markers of glutamatergic neurotransmission and oxidatives stress associated with tardive dyskinesia. Am. J. Psych. 155 (1998) 1207-1213
70. Ukai W., Ozawa H., Tateno M., Hashimoto E., and Saito T. Neurotoxic potential of haloperidol in comparison with risperidone. Implication of Akt-mediated signal changes by haloperidol. J. Neural Transm. 111 (2004) 667-681
71. Usuki E., Pearce R., Parkinson A., and Castagnoli N. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurons pyridinium metabolites by human liver microsomes. Chem. Res. Toxicol. 9 (1996) 800-806
72. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., and Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2837-2842
73. Vyas S., Javoy-Agid F., Herrero M.T., Strada O., Boissiere F., Hibner U., and Agid Y. Expression of bcl-2 in adult human brain regions with special reference to neurodegenerative disorders. J. Neurochem. 69 (1997) 223-231
74. Waddington J.L. Rodent and other animal models of tardive dyskinesia during long-term neuroleptic drug administration. Controversies and implications for the clinical syndrome. Neuroleptic-Induced Movements Disorders (1997), Cambridge Univ. Press, New York 225-237
75. Wei Z., Mousseau D.D., Dai Y., Cao X., and Li X.M. Haloperidol induces apoptosis via the sigma-2 receptor system and Bcl-Xs. The Pharmacogenesis (2006) 1-10
76. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., and Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res. 788 (1998) 215-222
77. Yin X.M., Oltvai Z.N., and Korsmeyer S.J. BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerisation with Bax. Nature 369 (1994) 321-323
78. Yokoyama H., Kasai N., Ueda Y., Niwa R., Konaka R., Mori N., Tsuchihashi N., Matsue T., Ohya-Nishiguchi H., and Kamada H. In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. Free Radical Biol. Mol. 26 (1998) 1056-1060